0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover1107.95%IV294.74%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.2063Delta0.1459Gamma12.67Leverage Ratio-0.0827Theta0.0000Rho2.61Eff Leverage0.0005Vega
NRX Pharmaceuticals Stock Discussion
Set ready
Hope Therapeutics, Inc. and NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Announce Alignment With FDA on Pediatric Study Plan for NRX-100 (Ketamine)
loading zone
NRX Pharmaceuticals (Nasdaq:Nrxp) to Proceed With Two New Drug Applications in 2024; NRX-101 Has Been Returned to the Company for Filing
What is OCU400's market potential? If we take Ocugen's estimates seriously, it is mouthwatering. The biotech projects that OCU400 could earn approval in 2026. Ocugen thinks the therapy could generate between $30 billion and $47 billion in total revenue in the five years after approval. The company's market cap is about $488 million as of this writing. So by any standar...
No comment yet